Ballard Spahr is representing Cephalon, Inc. (Nasdaq: CEPH) in its acquisition of Gemin X Pharmaceuticals, Inc., for $225 million in an all-cash deal that augments Cephalon’s portfolio of cancer therapeutics. Cephalon will pay up to an additional $300 million upon the achievement of certain regulatory and sales milestones. The companies have signed a definitive merger agreement. Closing is subject to customary closing conditions.

Gemin X, a biopharmaceutical company, is developing a pipeline of targeted cancer therapeutics based on reactivating programmed forms of cell death through the inhibition of metabolism in cancer tumor cells.

The Ballard Spahr team was led by Brian D. Doerner and included Brian C. Meadows, D. Brian Shortell, Wayne R. Strasbaugh, Jason A. Leckerman, Gregory L. Seltzer, Amit Kakkar, D. Renee Applegate, and Job M. Itzkowitz.